These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 10568755

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence.
    Van Herck K, Van Damme P.
    J Med Virol; 2001 Jan; 63(1):1-7. PubMed ID: 11130881
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
    Van Damme P, Leroux-Roels G, Law B, Diaz-Mitoma F, Desombere I, Collard F, Tornieporth N, Van Herck K.
    J Med Virol; 2001 Sep; 65(1):6-13. PubMed ID: 11505437
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
    Kanra G, Yalçin SS, Ceyhan M, Yurdakök K.
    Turk J Pediatr; 2000 Sep; 42(2):105-8. PubMed ID: 10936974
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
    Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A.
    J Med Virol; 1994 Dec; 44(4):446-51. PubMed ID: 7897379
    [Abstract] [Full Text] [Related]

  • 14. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine.
    Maiwald H, Jilg W, Bock HL, Löscher T, Sonnenburg F.
    Vaccine; 1997 Mar; 15(4):346-8. PubMed ID: 9141202
    [Abstract] [Full Text] [Related]

  • 15. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA.
    Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, Kuter BJ, Nalin DR.
    J Med Virol; 1996 Jul; 49(3):235-41. PubMed ID: 8818971
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination.
    Totos G, Gizaris V, Papaevangelou G.
    Vaccine; 1997 Aug; 15(11):1252-3. PubMed ID: 9286052
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Safety and immunogenicity of a new inactivated hepatitis A vaccine].
    Ren A, Ma J, Feng F.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.